ABA SVP Paul Benda discusses getting a booster shot if you’ve had Johnson and Johnson vaccine, delta variant-driven increases in cases in the central part of the country, how delta has affected the U.K. and Israel, a Kaiser Family Foundation survey about businesses and vaccines, the real risk from vaccine-induced myocarditis and a new paper that provides hope that most of the population may not need any booster shots.

ABA SVP Paul Benda covers the Delta variant of COVID-19 and its impact on younger populations, reviews vaccine effectiveness, looks at computer models and where they think we’ll be this fall, reviews a new study on how well vaccines work on those with cancer and examines how birthday parties may have contributed to the spread of COVID.

ABA's Paul Benda discusses about some new vaccine data from Novavax, the effect the Delta variant is having on the UK and how it’s spreading in the U.S., the FDA meeting regarding vaccinations for kids, whether vaccines causing heart inflammation and some updates on the legality of vaccine mandates and OSHA’s emergency temporary standard.

ABA SVP Paul Benda talks about the race to get 70% of the population vaccinated, reviews recovered immunity and what it might mean for the summer and fall, discusses some concerning data around the COVID-19 delta variant that originated in India, and look at the CDC study around hospitalized adolescents that concerned CDC Director Rochelle Walensky.

ABA SVP Paul Benda discusses the WHO naming convention of new COVID-19 variants, the impact one of those variants is having on the United Kingdom and what it means for the U.S., metrics that may determine when we get booster shots, new summer camp guidance from the CDC, EEOC update on rules surrounding workers and vaccinations and a brief update on regulators' back-to-work plans.

ABA SVP Paul Benda reviews vaccination progress and case counts, takes a detailed look at vaccine effectiveness against the primary strain circulating in India, gives an update on Moderna’s plans, reviews a new article on durability of recovered immunity, shares some good news and bad news for pregnant women, revisits the theory on COVID escaping from a Wuhan lab, and examines how the pandemic may evolve and end.

ABA SVP Paul Benda covers the updated CDC guidance on masks and what it means for banks and discusses the latest vaccination and infection rates. He also provides a brief but worrying comparison of infection rates of the current pandemic with the 1918 pandemic, reviews some vaccine effectiveness data, talks about booster shots and reviews some of the history around the aerosolization debate.

ABA SVP Paul Benda examines progress on vaccinations, an update on Pfizer’s availability for teens (including a look at how these vaccines work and whether he’d get one for his own child), good news on current case counts, where we may be this summer and what our long-term outlook may look like. 

ABA SVP Paul Benda provides an update on the vaccination rollout, takes a look at new CDC infection estimates and what it means for herd immunity, shares a round-up on vaccine news and when the Pfizer shots will be available for kids and teens, discusses whether herd immunity is even achievable, and examines OSHA’s latest moves.

ABA's Paul Benda provides an update on India and some of the help the U.S. plans to provide, talks about the Johnson and Johnson vaccine after the FDA decision, discusses breakthrough infections in a Kentucky nursing home and why there’s some good news there, goes through an MIT paper on uselessness of social distancing indoors and examines vaccine passports.